Ed Kaye, Stoke Therapeutics CEO
December 3, 2021 10:00 AM ESTUpdated 11:39 AM
R&D

Stoke touts ear­ly signs of ef­fi­ca­cy for Dravet syn­drome drug

Nicole DeFeudis

Editor

Two and a half years af­ter dri­ving his an­ti­sense oligonu­cleotide plat­form to Wall Street, Stoke Ther­a­peu­tics CEO Ed Kaye is paint­ing a fuller pic­ture of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

A service from the Financial Times